Login

Switch On Your HIV Smarts.

Author Archives: Liz Highleyman

Two new HIV drugs, Doravirine and Bictegravir, suppress viral loads in studies and proceed to Phase 3 testing

Two new HIV drugs, Doravirine and Bictegravir, suppress viral loads in studies and proceed to Phase 3 testing

, by Liz Highleyman

Two new HIV drugs, an NNRTI and an integrase inhibitor, did well in clinical trials and are currently being tested as part of fixed-dose co-formulated pills. Read More

Simpler HIV treatment, with only 2 drugs, keeps viral loads suppressed

Simpler HIV treatment, with only 2 drugs, keeps viral loads suppressed

, by Liz Highleyman

People taking only two drugs, dolutegravir and rilpivirine, maintained viral suppression in participants of the SWORD-1 an SWORD-2 studies. Read More

Timothy Brown, the Berlin Patient, Celebrates a Decade Cured of HIV

Timothy Brown, the Berlin Patient, Celebrates a Decade Cured of HIV

, by Liz Highleyman

The only person cured of HIV, Brown now takes Truvada as PrEP to prevent a new HIV infection. Read More

High sexually transmitted infection rates spur condom debate

High sexually transmitted infection rates spur condom debate

, by Liz Highleyman

What’s causing the rising STI rates? And, do rising STI rates mean that we should be promoting condom use for everyone? Read More

For people with drug resistant HIV, monoclonal antibody shows promise as “rescue” therapy

For people with drug resistant HIV, monoclonal antibody shows promise as “rescue” therapy

, by Liz Highleyman

A monoclonal antibody shows promise for people living with HIV who are “left behind,” with few HIV treatment options, when current antiretrovirals fail from drug resistance. Read More